Insider Sells AGIO Shares Worth $82,000 -- But Context Is Everything

The company’s business model centers on the discovery, development, and commercialization of innovative medicines for rare hematologic diseases.Agios Pharmaceuticals develops and commercializes therapeutics targeting cellular metabolism, with its lead product, PYRUKYND (mitapivat), for hemolytic anemias, and AG-946 in Phase I clinical trials.How does this trade relate to historical activity? Krishnan joined Agios on March 5, 2025, making this transaction his one-year employment anniversary and the first ves ...